Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact".
The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago.
Non-GAAP diluted earnings per share came in at $0.52, an 8% increase from the prior year.
Austedo (deutetrabenazine) generated $411 million in sales, up 39% year-on-year, prompting Teva to raise its full-year revenue forecast for the product to between $1.95 billion and $2.05 billion. Migraine treatment Ajovy (fremanezumab-vfrm) achieved global revenues of $139 million, rising 26%, while schizophrenia treatment Uzedy (a risperidone extended-release injectable suspension) contributed $39 million.
Teva’s generics business also delivered growth across all regions, with a 5% increase in the US, 1% in Europe, and 2% in international markets.
CEO Richard Francis noted that the company is making progress on its “Pivot to Growth” strategy while also recording its ninth consecutive quarter of revenue growth.
"We’re accelerating innovative growth and strengthening our generics business, while streamlining our operations," he said.
Teva maintained its 2025 full-year revenue outlook of $16.8-17.2 billion, with adjusted EBITDA of $4.7-5 billion expected.